Company: NCEL
Filing Date: 2025-03-03
Form Type: F-4/A
Source: 0001213900-25-018981
Chunk: 346

Company: NewcelX Ltd.
Filing Date: 2025-03-03
Form: F-4/A
Chunk 346
---
                  |       4,207 |   |     |             |           — |   |     |       |     |             |          — |   |     |       |     |           |    (937,095 | ) |
| Total shareholders’ (deficit) equity                                                                                                                                                                   |     |               |  (2,166,533 | ) |     |                  |  (9,268,258 | ) |     |             |  19,464,758 |   |     |       |     |             |  4,643,522 |   |     |       |     |           |  12,673,488 |   |
| Total Liabilities and Shareholders’ (Deficit) Equity                                                                                                                                                   |     | $             |   1,429,636 |   |     | $                |   1,193,458 |   |     | $           |  10,004,327 |   |     |       |     | $           |  2,100,000 |   |     |       |     | $         |  14,727,420 |   |

The accompanying notes are an integral part of these unaudited pro forma condensed combined financial statements.

192

Kadimastem Ltd. & NLS Pharmaceutics Ltd.
Unaudited Pro Forma Condensed Combined Statement of Operations and Other Comprehensive Loss

|                                                                                              |     | For the Six Months Ended June 30, 2024 |            |                  |     |   |            |             |     |   |          |       |     |             |     |   |         |     |           |     |   |            |   |
|:---------------------------------------------------------------------------------------------|:----|:---------------------------------------|-----------:|:-----------------|:----|:--|-----------:|:------------|:----|:--|---------:|:------|:----|:------------|:----|:--|--------:|:----|:----------|:----|:--|-----------:|:--|
| Kadimastem,                                                                                  
 Ltd.                                                                                         |     |                                        |            | NLS              
 Pharmaceuticals, 
 Ltd.             |     |   |            | Pro Forma   
 Adjustments 
 NLS         |     |   |          | Notes |     | Pro Forma   
 Adjustments 
 Kadimastem  |     |   |   Notes |     | Pro Forma 
 Combined  |